Participant-centric study design has advanced, but site-centric execution has not kept pace. In the Journal for Clinical Studies, Brian Mallon examines how unclear expectations, administrative burden and contract delays ...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Harmonising outsourcing to keep clinical trials on track
In this article in Applied Clinical Trials, Debbie Gilmore, Vice President, Strategic Alliance Management outlines how strategic partnerships and partnership-driven approaches to outsourcing can be used to navigate an increasingly complex clinical research landscape.
-
Modern partnerships with CROs
In this article in Contract Pharma, ICON SMEs share insight on strategic and blended outsourcing models and trends in today’s market.
-
ICON partners with US Government for clinical trials of Covid-19 vaccines
The article on Clinical Trials Arena reports that ICON will conduct a phase 2b clinical trial for the US BARDA-selected Covid-19 vaccine candidate as part of Project NextGen.
-
BARDA, ICON partner to execute next-gen COVID vaccine trial
This news article from Contract Pharma reports that ICON will execute a Phase 2b clinical trial to assess the relative efficacy of a next generation COVID-19 vaccine.
-
ICON to partner with US government agency to test COVID vaccine candidates
This news article from Reuters outlines that, as part of the collaboration with Biomedical Advanced Research and Development Authority, ICON will conduct a mid-stage trial of 10,000 participants to assess the efficacy of a next generation COVID-19 vaccine relative to currently available shots.
-
ICON to conduct U.S. government trial of next-gen COVID-19 vaccines
This news article, published on FIERCE Biotech, highlights that ICON is partnering with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) to conduct a clinical trial to evaluate next-generation vaccines for COVID-19.
-
LEO Pharma enters clinical trial partnership with ICON
This news article, published on PM Live, highlights how the partnership will advance trial execution within medical dermatology.
-
LEO Pharma and ICON partner for clinical trial execution in dermatology
This news article, published on Clinical Trials Arena, outlines how the collaboration is expected to provide access to innovative clinical trials as well as help to launch new medicines.
-
LEO Pharma and ICON enter strategic partnership
This news article, first published on Applied Clinical Trials, outlines that LEO Pharma and ICON have announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective.
-
ICON and LEO Pharma join forces on clinical trial mission
This news article, published on PharmaTimes online, indicates how the collaboration will concentrate on launching and running studies within medical dermatology.
